Početna › Multipli mijelom › Oregon
Kliničke studije za Multipli mijelom u državi Oregon
20 studija za Multipli mijelom traži sudionike na lokacijama u državi Oregon.
Gradovi u državi Oregon
Službeni tekst studije (engleski)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Portland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center, Eugene
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Oregon Health And Science University, Portland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07258511Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT06784167A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Willamette Valley Cancer Institute and Research Center /ID# 278721, Eugene
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Providence Health & Services, Portland
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Oregon Health and Science University /ID# 272282, Portland
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06953960A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center, Eugene
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07637578A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07075185Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Portland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT07764978Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. srp 2026. · NCT05469893A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Willamette Valley Cancer Institute and Research Center /ID# 267088, Eugene
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- Providence Cancer Institute Clackamas Clinic, Clackamas
- i još 7
U tijeku regrutacijaFaza 3
Sve dobne skupine · Oba spola · Ažurirano 10. lip 2026. · NCT05561387Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Oncology Associates of Oregon, Eugene
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT05972135Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 20. tra 2026. · NCT03761108A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 24. ožu 2026. · NCT04988555Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Local Institution - 0016, Portland
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 22. sij 2026. · NCT06357754cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Oregon Health Sciences University, Portland
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 godina i više · Oba spola · Ažurirano 20. sij 2026. · NCT05366881Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.